Abstract
Most cases of breast and prostate cancer are not associated with mutations in known high-penetrance genes, indicating the involvement of multiple low-penetrance risk alleles. Studies that have attempted to identify these genes have met with limited success. The National Cancer Institute Breast and Prostate Cancer Cohort Consortium ? a pooled analysis of multiple large cohort studies with a total of more than 5,000 cases of breast cancer and 8,000 cases of prostate cancer ? was therefore initiated. The goal of this consortium is to characterize variations in approximately 50 genes that mediate two pathways that are associated with these cancers ? the steroid-hormone metabolism pathway and the insulin-like growth factor signalling pathway ? and to associate these variations with cancer risk.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lichtenstein, P. et al. Environmental and heritable factors in the causation of cancer ? analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343, 78?85 (2000).
Pharoah, P. D., Dunning, A. M., Ponder, B. A. & Easton, D. F. Association studies for finding cancer-susceptibility genetic variants. Nature Rev. Cancer 4, 850?860 (2004).
Pollak, M. N., Schernhammer, E. S. & Hankinson, S. E. Insulin-like growth factors and neoplasia. Nature Rev. Cancer 4, 505?518 (2004).
Feigelson, H. S. et al. Cytochrome P450c17α gene (CYP17) polymorphism predicts use of hormone replacement therapy. Cancer Res. 59, 3908?3910 (1999).
Thompson, P. A. & Ambrosone, C. Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J. Natl Cancer Inst. Monogr. 27, 125?134 (2000).
Feigelson, H. S., Coetzee, G. A., Kolenel, L. N., Ross, R. K. & Henderson, B. E. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 57, 1063?1065 (1997).
Haiman, C. A. et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res. 59, 1015?1020 (1999).
Henderson, B. E. & Feigelson, H. S. Hormonal carcinogenesis. Carcinogenesis 21, 427?433 (2000).
Thomas, H. V. et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br. J. Cancer 75, 1075?1079 (1997).
Hankinson, S. E. et al. Plasma sex steriod hormone levels and risk of breast cancer in postmenopausal women. J. Natl Cancer Inst. 90, 1292?1299 (1998).
Cauley, J. A. et al. Elevated serum estradiol and testosterone concentrations are associated with high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann. Intern. Med. 130, 270?277 (1999).
Key, T., Appleby, P., Barnes, I. & Reeves, G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl Cancer Inst. 94, 606?616 (2002).
Key, T. J. & Pike, M. C. The role of oestrogens and progestogens in the epidemiology and prevention of breast cancer. Eur. J. Cancer Clin. Oncol. 24, 29?43 (1988).
Bernstein, L. & Ross, R. Endogenous hormones and breast cancer risk. Epidemiol Rev. 15, 48?65 (1993).
Ross, R. K., Paganini-Hill, A., Wan, P. C. & Pike, M. C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J. Natl Cancer Inst. 92, 328?332 (2000).
Olsson, H., Bladstrom, A., Ingvar, C. & Moller, T. R. A population-based cohort study of HRT use and breast cancer in southern Sweden. Br. J. Cancer 85, 674?677 (2001).
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 347, 1713?1727 (1996).
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiologic studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350, 1047?1059 (1997).
Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321?333 (2002).
Anderson, G. L. et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291, 1701?1712 (2004).
Kolonel, L. N., Altshuler, D. & Henderson, B. E. The Multiethnic Cohort study: exploring genes, lifestyle and cancer risk. Nature Rev. Cancer 4, 519?527 (2004).
Secreto, G. & Zumoff, B. Abnormal production of androgens in women with breast cancer. Anticancer Res. 14, 2113?2117 (1994).
Kaaks, R. Nutrition, hormones, and breast cancer: is insulin the missing link? Cancer Causes Control 7, 605?625 (1996).
Ehrmann, D. A., Barnes, R. B. & Rosenfield, R. I. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenis due to dysregulation of androgen secretion. Endocr. Rev. 16, 322?353 (1995).
Zhu, B. T. & Conney, A. H. Functional role of estrogen metabolism in target cells: review and perspective. Carcinogenesis 19, 1?27 (1998).
Jefcoate, C. R. et al. Tissue-specific synthesis and oxidative metabolism of estrogens. J. Natl Cancer Inst. Monogr. 27, 95?112 (2000).
Yue, W. et al. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J. Steroid Biochem. Mol. Biol. 86, 477?486 (2003).
Zhu, Y. S., Katz, M. D. & Imperato-McGinley, J. Natural potent androgens: lessons from human genetic models. Baillieres Clin. Endocrinol. Metab. 12, 83?113 (1998).
Ball, P. & Knuppen, R. Catecholoestrogens (2-and 4-hydroxyoestrogens): chemistry, biogenesis, metabolism, occurrence and physiological significance. Acta Endocrinol. Suppl. (Copenh.) 232, 1?127 (1980).
Martucci, C. P. & Fishman, J. P450 enzymes of estrogen metabolism. Pharma. Ther. 57, 237?257 (1993).
Randall, V. A. Role of 5 α-reductase in health and disease. Baillieres Clin. Endocrinol. Metab. 8, 405?431 (1994).
Bosland, M. C. Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal products. Prog. Clin. Biol. Res. 394, 309?352 (1996).
Lookingbill, D. P. et al. Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J. Clin. Edocrinol. Metab. 72, 1242?1248 (1991).
van Houten, M. E. & Gooren, L. J. Differences in reproductive endocrinology between Asian men and Caucasian men?a literature review. Asian J. Androl. 2, 13?20 (2000).
Platz, E. A. & Giovannucci, E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J. Steroid Biochem. Mol. Biol. 92, 237?253 (2004).
Kaaks, R., Lukanova, A. & Sommersberg, B. Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic Dis. 3, 157?172 (2000).
Yu, H. & Rohan, T. Role of the insulin-like growth factor family in cancer development and progression. J. Natl. Cancer Inst. 92, 1472?1489 (2000).
Khandwala, H. M., McCutcheon, I. E., Flyvbjerg, A. & Friend, K. E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev. 21, 215?244 (2000).
Kaaks, R. & Lukanova, A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc. Nutr. Soc. 60, 91?106 (2001).
Peyrat, J. P. et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur. J. Cancer 29A, 492?497 (1993).
Bohlke, K., Cramer, D. W., Trichopoulos, D. & Mantzoros, C. S. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 9, 570?573 (1998).
Toniolo, P. et al. Serum insulin-like growth factor-I and breast cancer. Int. J. Cancer 88, 828?832 (2000).
Hankinson, S. E. et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351, 1393?1396 (1998).
Hall, K., Hilding, A. & Thoren, M. Determinants of circulating insulin-like growth factor-I. J. Endocrinol Invest. 22, 48?57 (1999).
Hong, Y., Brismar, K., Hall, K., Pedersen, N. L. & de Faire, U. Associations between insulin-like growth factor-I (IGF-I), IGF-binding protein-1, insuin and other metabolic measures after controlling for genetic influences: results from middle-aged and elderly monozygotic twins. J. Endocrinol. 153, 251?257 (1997).
Harrela, M. et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J. Clin. Invest. 98, 2612?2615 (1996).
Lopez-Bermejo, A., Buckway, C. K. & Rosenfeld, R. G. Genetic defects of the growth hormone-insulin-like growth factor axis. Trends Endocrinol. Metab. 11, 39?49 (2000).
Jernstrom, H. et al. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol. Biomarkers Prev. 10, 377?384 (2001).
Rasmussen, S. K. et al. Studies of the variability of the genes encoding the insulin-like growth factor I receptor and its ligand in relation to type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 85, 1606?1610 (2000).
Sun, G., Chagnon, M. & Bouchard, C. A common polymorphism in the human insulin-like growth factor binding protein 3 gene. Mol. Cell. Probes 14, 55?56 (2000).
Sasi, R., Puebla, L., Khare, S. & Patel, Y. C. Polymorphism in the 5′ flanking region of the human somatostatin receptor subtype 5. Gene 214, 45?49 (1998).
Mantzoros, C. S. et al. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br. J. Cancer 76, 1115?1118 (1997).
Wolk, A. et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl Cancer Inst. 90, 911?915 (1998).
Chokkalingam, A. P. et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol. Biomarkers. Prev. 10, 431?437 (2001).
van den Brandt, P. A. et al. Pooled analysis of prospective cohort studies on height, weight and breast cancer risk. Am. J. Epidemiol. 152, 514?527 (2000).
Siiteri, P. K. Adipose tissue as a source of hormones. Am. J. Clin. Nutr. 45, 277?282 (1987).
Austin, H., Austin, J. M., Jr., Partridge, E. E., Hatch, K. D. & Shingleton, H. M. Endometrial cancer, obesity, and body fat distribution. Cancer Res. 51, 568?572 (1991).
Newcomb, P. A. et al. Association of dietary and life-style factors with sex hormones in postmenopausal women. Epidemiol. 6, 318?321 (1995).
Franks, S. Polycystic ovary syndrome. N. Engl. J. Med. 333, 853?861 (1995).
Dunaif, A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr. Rev. 18, 774?800 (1997).
Urbanek, M. et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc. Natl Acad. Sci. USA 96, 8573?8578 (1999).
Legro, R. S. et al. Phenotype and genotype in polycystic ovary syndrome. Recent Prog. Hormone Res. 53, 217?256 (1998).
De Cree, C. et al. Response of catecholestrogen metabolism to acute graded exercise in normal menstruating women before and after training. J. Clin. Endocrinol. Metab. 82, 3342?3348 (1997).
Haiman, C. A., Hankinson, S. E., Colditz, G. A., Hunter, D. J. & De Vivo, I. A polymorphism in CYP17 and endometrial cancer risk. Cancer Res. 61, 3955?3960 (2001).
McKean-Cowdin, R. et al. Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. Cancer Res. 61, 848?849 (2001).
Michnovicz, J. J., Naganuma, H., Hershcopf, R. J., Bradlow, H. L. & Fishman, J. Increased urinary catechol estrogen excretion in female smokers. Steroids 52, 69?83 (1988).
Couch, F. J. et al. Cigarette smoking increases risk for breast cancer in high-risk breast cancer families. Cancer Epidemiol. Biomarkers Prev. 10, 327?332 (2001).
Johnson, K. C., Hu, J. & Mao, Y. Passive and active smoking and breast cancer risk in Canada, 1994?97. The Canadian Cancer Registries Epidemiology Research Group. Cancer Causes Control 11, 211?221 (2000).
Terry, P. D. & Rohan, T. E. Cigarette smoking and the risk of breast cancer in women: a review of the literature. Cancer Epidemiol. Biomarkers Prev. 11, 953?971 (2002).
Mitrunen, K. & Hirvonen, A. Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat Res. 544, 9?41 (2003).
Packer, B. R. et al. SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Res. 32, D528?D532 (2004).
Calle, E. E. et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer 94, 2490?2501 (2002).
The α-Tocopherol β-Carotene Cancer Prevention Study Group. The α-Tocopherol β-Carotene Lung Cancer Prevention Study: design, methods, participant characteristics, and compliance. Ann. Epidemiol. 4, 1?10 (1994).
Riboli, E. et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 5, 1113?1124 (2002).
Hayes, R. B. et al. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin. Trials 21, 349S?355S (2000).
Sesso, H. D. et al. Comparison of baseline characteristics and mortality experience of participants and nonparticipants in a randomized clinical trial: the Physicians' Health Study. Control Clin. Trials 23, 686?702 (2002).
Chan, J. M. et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J. Natl Cancer Inst. 94, 1099?1106 (2002).
Giovannucci, E. et al. Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol. Biomarkers Prev. 12, 84?89 (2003).
Wacholder, S., Chanock, S., Garcia-Closas, M., El Ghormli, L. & Rothman, N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J. Natl Cancer Inst. 96, 434?442 (2004).
Cara, J. F. Insulin-like growth factors, insulin-like growth factor binding proteins and ovarian androgen production. Horm. Res. 42, 49?54 (1994).
Lin, T., Haskell, J., Vinson, N. & Terracio, L. Direct stimulatory effects of insulin-like growth factor-I on Leydig cell steroidogenesis in primary culture. Biochem. Biophys. Res. Commun. 137, 950?956 (1986).
Stram, D. O. et al. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum. Hered. 55, 27?36 (2003).
Carlson, C. S. et al. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am. J. Hum. Genet. 74, 106?120 (2004).
Botstein, D. & Risch, N. Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nature Genet. 33 (suppl.), 228?237 (2003).
Cargill, M. et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nature Genet. 22, 231?238 (1999).
Li, W. H. & Sadler, L. A. Low nucleotide diversity in man. Genetics 129, 513?523 (1991).
Halushka, M. K. et al. Patterns of single-nucleotide polymorphisms in candidate genes fro blood-pressure homeostatsis. Nature Genet. 22, 239?247 (1999).
Sachidanandam, R. et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409, 928?933 (2001).
Marth, G. et al. Single-nucleotide polymorphisms in the public domain: how useful are they? Nature Genet. 27, 371?372 (2001).
Gabriel, S. B. et al. The structure of haplotype blocks in the human genome. Science 296, 2225?2229 (2002).
Harpending, H. & Rogers, A. Genetic perspectives on human origins and differentiation. Annu. Rev. Genomics Hum. Genet. 1, 361?385 (2000).
Sabeti, P. C. et al. Detecting recent positive selection in the human genome from haplotype structure. Nature 419, 832?837 (2002).
Rosand, J. & Altshuler, D. Human genome sequence variation and the search for genes influencing stroke. Stroke 34, 2512?2516 (2003).
Edwards, A. O. et al. Complement factor H polymorphism and age-related macular degeneration. Science 308, 421?424 (2005).
Klein, R. J. et al. Complement factor H polymorphism in age-related macular degeneration. Science 308, 385?389 (2005).
Haines, J. L. et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 308, 419?421 (2005).
Acknowledgements
The authors gratefully acknowledge the participants in the component cohort studies, and the expert contributions of: Hardeep Ranu, Craig Labadie, Lisa Cardinale and Shamika Ketkar from Harvard University, USA; William Modi, Merideth Yeager, Robert Welch, Cynthia Glaser and Laurie Burdett from the National Cancer Institute; Mourad Sahbatou and Emmanuel Tubacher from Centre d'Etude du Polymorphism Humain; and Loreall Pooler, Stephanie Riley, John Casagrande and Reed Comire from the University of Southern California, USA.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The author declare no competing financial interests.
Additional information
Members of the BPC3 who have agreed to be named are listed in Box 2.
Related links
Related links
DATABASES
Entrez Gene
National Cancer Institute
FURTHER INFORMATION
Core genotyping facility website of the NCI
Haplotype tagging SNP (htSNP) selection in the Multiethnic Cohort Study
Rights and permissions
About this article
Cite this article
The National Cancer Institute Breast and Prostate Cancer Cohort Consortium. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer 5, 977–985 (2005). https://doi.org/10.1038/nrc1754
Issue Date:
DOI: https://doi.org/10.1038/nrc1754
This article is cited by
-
CYP2C8 rs11572080 and CYP3A4 rs2740574 risk genotypes in paclitaxel-treated premenopausal breast cancer patients
Scientific Reports (2024)
-
Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival
BMC Medical Genomics (2020)
-
Integrative genomic analysis implicates ERCC6 and its interaction with ERCC8 in susceptibility to breast cancer
Scientific Reports (2020)
-
Association between the insulin-like growth factor 1 gene rs2195239 and rs2162679 polymorphisms and cancer risk: a meta-analysis
BMC Medical Genetics (2019)
-
Validating a breast cancer score in Spanish women. The MCC-Spain study
Scientific Reports (2018)